Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma

Chinese Medical Journal

Volumn 126, Issue 3, 2013, Pages 482-487

  Chen, Bo bin ^a   Xu, Xiao Ping ^a   Shen, Lin ^a   Han, Tian Jie ^a   Lin, Zhi guang ^a   Chen, Zi ^a   Kang, Hui ^a   Huang, Bo ^a   Lin, Guo Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cyclin D3; Cyclin E; Immunochemohistorical marker; Primary central nervous system lymphoma; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D3; CYCLIN E; GLOBULIN; HERMES ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP2;

ADULT; AGE; AGED; ANTIGEN EXPRESSION; ARTICLE; BIOPSY; CANCER PROGNOSIS; CHEMICAL ANALYSIS; COHORT ANALYSIS; FEMALE; FRONTAL LOBE; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LIM DOMAIN ONLY 2 GENE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; RETROSPECTIVE STUDY; SURVIVAL RATE; THALAMUS; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLIN D3; CYCLIN E; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LIM DOMAIN PROTEINS; LYMPHOMA; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84873425318     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20120844     Document Type: Article

References (36)

1. Haldorsen IS, Krossnes BK, Aarseth JH, Scheie D, Johannesen TB, Mella O, et al. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003: time trends in a 15-year national survey. Cancer 2007; 110: 1803-1814.
2. Bhagavathi S, Wilson JD. Primary central nervous system lymphoma. Arch Pathol Lab Med 2008; 132: 1830-1834.
3. Liu BL, Cheng JX, Zhang X, Zhang W, Cheng H. Limited role of surgery in the management of primary central nervous system lymphoma. Oncol Rep 2009; 22: 439-449.
4. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 2011; 76: 929-930.
5. Swinnen LJ. Primary central nervous system lymphoma: recent progress, many remaining questions. Curr Opin Oncol 2009; 21: 393-396.
6. Sierra del Rio M, Rousseau A, Soussain C, Ricard D, Hoang-Xua K. Primary CNS lymphoma in immunocompetent patients. Oncologist 2009; 14: 526-539.
7. Campen CJ, Tombleson RL, Green MR. High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma. J Neurooncol 2011; 101: 345-355.
8. Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol 2011; 101: 487-493.
9. Reni M, Ferreri AJ, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997; 8: 227-234.
10. Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 2011; 101: 257-265.
11. Kawai N, Zhen HN, Miyake K, Yamamaoto Y, Nishiyama Y, Tamiya T, et al. Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment. J Neurooncol 2010; 100: 225-232.
12. Illerhaus G, Marks R, Muller F, Ihorst G, Feuerhake F, Deckert M, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009; 20: 319-325.
13. Schuurmans M, Bromberg JE, Doorduijn J, Poortmans P, Taphoorn MJ, Seute T, et al. Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis. Br J Haematol 2010; 151: 179-184.
14. Ney DE, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2010; 116: 4605-4612.
15. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24: 5711-5715.
16. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266-2672.
17. Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, et al. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 2004; 59: 501-508.
18. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
19. Metcalf RA, Zhao S, Anderson MW, Lu ZS, Galperin I, Marinelli RJ, et al. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Mod Pathol 2010; 23: 420-433.
20. Moller MB. Molecular control of the cell cycle in cancer: biological and clinical aspects. Dan Med Bull 2003; 50: 118-138.
21. Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 2002; 8: 729-733.
22. Tzankov A, Gschwendtner A, Augustin F, Fiegl M, Obermann EC, Dirnhofer S, et al. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clin Cancer Res 2006; 12: 2125-2132.
23. Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008; 26: 447-454.
24. Natkunam Y, Zhao S, Mason DY, Hans CP, Tibshirani R, Sehn LH, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007; 109: 1636-1642.
25. Hoeller S, Schneider A, Haralambieva E, Dirnhofer S, Tzankov A. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology 2010; 57: 73-80.
26. Kluin PK, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: Steven H, Swerdlow EC, Nancy LH, Elaine SJ, Stefano AP, Harald S, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008: 240-241.
27. Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001; 19: 551-557.
28. Huang H, Lu ZW, Jiang CG, Li J, Xu K, Xu ZJ. Clinical and prognostic characteristics of pulmonary mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 23 cases in a Chinese population. Chin Med J 2011; 124: 1026-1030.
29. Li HJ, Cheng JL. AIDS complicated with intestinal lymphoma: X-ray radiology, CT scan and pathological findings. Chin Med J 2011; 124: 1427-1430.
30. Preusser M, Woehrer A, Koperek O, Rottenfusser A, Dieckmann K, Gatterbauer B, et al. Primary central nervous system lymphoma: a clinicopathological study of 75 cases. Pathology 2010; 42: 547-552.
31. Raoux D, Duband S, Forest F, Trombert B, Chambonniere ML, Dumollard JM, et al. Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance. Neuropathology 2010; 30: 232-240.
32. Song MK, Chung JS, Joo YD, Lee SM, Oh SY, Shin DH, et al. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma. J Neurooncol 2011; 104: 825-831.
33. Grulich AE, Wan X, Law MG, Milliken ST, Lewis CR, Garsia RJ, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14: 133-140.
34. Parker D, Alison DL, Barnard DL, Child JA, Dovey G, Farish J, et al. Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level. Hematol Oncol 1994; 12: 15-27.
35. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Child JA, Dovey G, Farish J, et al. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur J Haematol 2009; 82: 364-372.
36. Courts C, Brunn A, Montesinos-Rongen M, Siemer D, Hans V, Paulus W, et al. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma. J Neuropathol Exp Neurol 2009; 68: 972-976.